• Canada
• Research dataclose
• 2021-2021close
• Dataset close
• Canadian Institutes of Health Research close

Related Article: Sumanta Garai, Luciana M. Leo, Anna-Maria Szczesniak, Dow P. Hurst, Peter C. Schaffer, Ayat Zagzoog, Tallan Black, Jeffrey R. Deschamps, Elke Miess, Stefan Schulz, David R. Janero, Alex Straiker, Roger G. Pertwee, Mary E. Abood, Melanie E. M. Kelly, Patricia H. Reggio, Robert B. Laprairie, Ganesh A. Thakur|2021|J.Med.Chem.|64|8104|doi:10.1021/acs.jmedchem.1c00040

Additional file 12: Table S1. Total number of ones, zeros and nulls in the sparse matrix for the 163 TFs used in this study.

Additional file 6: Table S1. Comparison of COSMIC mutational signature contributions to non-seminomatous (n = 56) and seminomatous (n = 44) testicular tumors. Entries are number (proportion) of cases with a signature present above a threshold of 6% in each histologic group. P-values were calculated adjusting for age of onset * indicates statistical significance at a 0.05 level.

Additional file 3 : Table S2. Exact file IDs and links to all data obtained from ENCODE and Roadmap Epigenome.

A common feature of solid tumours that are resistant to therapy is the presence of regions with low oxygen content (i.e., hypoxia). Oxygen electrode studies suggest that localized prostate adenocarcinoma is commonly hypoxic, although conflicting data have been reported between immunohistochemical detection of hypoxia-induced proteins in biopsy specimens and positron emission tomography (PET) imaging of 18F-labeled hypoxia reporters. Although the 2-nitroimidazole 18F-EF5 is well-established to label hypoxic tumour cells in pre-clinical tumour models and clinical trials of multiple primary tumour sites, it has yet to be tested in prostate cancer. The purpose of this study was to evaluate the feasibility of using 18F-EF5 to detect hypoxia in clinical prostate tumours. Patients with localized adenocarcinoma of the prostate were recruited for pre-treatment 18F-EF5 PET scans. Immunohistochemistry was conducted on diagnostic biopsies to assess the expression of glucose transporter 1 (GLUT1), osteopontin (OPN), and carbonic anhydrase IX (CAIX). Immunoreactivity scores of staining intensity and frequency were used to indicate the presence of tumour hypoxia. We found low tumour-to-muscle ratios of 18F-EF5 uptake that were not consistent with tumour hypoxia, causing early termination of the study. However, we observed GLUT1 and OPN expression in all prostate tumour biopsies, indicating the presence of hypoxia in all tumours. Our data do not support the use of 18F-EF5 PET to detect hypoxia in prostate adenocarcinoma, and suggest the use of immunohistochemistry to quantify expression of the hypoxia-inducible proteins GLUT1 and OPN as indications of prostate tumour hypoxia.

Additional file 1.

Additional file 3: Table S2. P-values for upregulation of indicated genes and transposons.

Supplemental material, sj-xlsx-3-smm-10.1177_09622802211002861 for A method for systematically ranking therapeutic drug candidates using multiple uncertain screening criteria by Xubiao Peng, Ebrima Gibbs, Judith M Silverman, Neil R Cashman and Steven S Plotkin in Statistical Methods in Medical Research

Additional file 2: Ontario Institute for Cancer Research (OICR) Tool Compound Library.

Supplemental Material, sj-r-1-jbd-10.1177_01650254211031631 for Solutions for latent growth modeling following COVID-19-related discontinuities in change and disruptions in longitudinal data collection by Charlie Rioux, Zachary L. Stickley and Todd D. Little in International Journal of Behavioral Development